Revolution Medicines' experimental drug, daraxonrasib, is being hailed as a "game changer" for pancreatic cancer, a disease known for its high mortality rate and late-stage diagnosis. Clinical trials demonstrated that patients with advanced pancreatic cancer treated with daraxonrasib lived a median of 13.2 months, a significant increase compared to 6.7 months for those receiving standard chemotherapy. This represents a 60 percent reduction in the risk of death.
The drug, an oral RAS(ON) multi-selective inhibitor, specifically targets KRAS gene mutations found in over 90% of pancreatic cancers. Although not yet fully FDA approved, it has been fast-tracked and is accessible to eligible patients through the FDA’s Expanded Access Protocol at select Intermountain Health hospitals and other institutions. Revolution Medicines has provided the drug free of charge during this program, with over two thousand patients in the U.S. currently receiving it.
Medical experts are calling this an extraordinary advance, with Dr. Reza Nazemzadeh stating it's "the most exciting thing in pancreas cancer in over a decade." The drug's efficacy extends beyond survival, as patients also reported significantly delayed deterioration in cancer-related pain and an improved quality of life. The New Drug Application for daraxonrasib was accepted for review by the FDA, supported by the Phase 3 RASolute 302 trial results, which were presented at the American Society of Clinical Oncology annual meeting and simultaneously published in The New England Journal of Medicine. The FDA has also granted daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation. While not a cure, it offers substantial prolongation of life for patients with this aggressive disease.
